Growing pain market to bode well for IX Biopharma

It has five drugs under development.

Combining with the sublingual delivery method to improve drug absorption and bioavailability to achieve a lower dosage, iX Biopharma’s products could potentially be key drugs in their respective market segments, said DBS Vickers Securities.

 iX Biopharma, a speciality pharmaceutical company with expertise in formulation and drug delivery, currently has five drugs under development – three are for pain management: WafermineTM, BnoXTM and WafernylTM; WafeRestTM for jetlag and improved sleep quality; and PheoniXTM for the treatment of male erectile dysfunction.

According to DBS Vickers Securities, the global pain management is growing, especially with the ageing population.

"We expect iX Biopharma to capture a significant market share once WafermineTM and BnoXTM are ready for commercialisation and exportation, likely in late 2018/ early 2019," it said.

The research firm added that to fund further R&D and clinical operations and to accelerate profitability, iX Biopharma could explore out-licensing opportunities likely in 3Q17.